Beschrijving

EmERGE will develop a mHealth platform to enable self-management of HIV in patients with stable disease. The
platform will build upon and integrate the existing mHealth solutions operated by pioneering healthcare providers in
the UK and Spain and apply a rigorous co-design approach to ensure patient and clinician input to the solution. The
platform will provide users with web based and mobile device applications which interface securely with relevant
medical data and facilitate remote access to key healthcare providers EATG, the European HIV patient organisation,
will provide a direct and deep interaction with representative patients and clinicians from 5 EU countries. The
platform and interfaces will be validated in a large study of 3900 patients using a tailored HTA process, MAST,
specifically developed for the assessment of mHealth solutions including translatability as a key factor. Based on prior
work showing a high uptake rate and use of mHealth in HIV patient populations, EmERGE aims to demonstrate the
benefits to patients and simultaneous increases in cost-effectiveness for healthcare providers by reducing face-toface
consultations, estimated at 6000 saved per year within this study alone. Patient reported outcomes will be agreed
and used in the assessment and development of the system which also aims to increase adherence and enable frailty
to be reported using mHealth technology. Innovation will be given priority from the beginning by developing new
business models of care provision, targeting key stakeholders in the EU health provider sector, including policymakers
and clinicians, while eliciting demand from patients to highlight and initiate the widespread implementation and
compensation of mHealth solutions within the timeframe of the project. Guidelines and policy briefs will be produced
to evidence the benefits and disseminate the lessons learned to support the uptake of mHealth for self-management of
other chronic diseases.
AcroniemEmERGE
StatusIn uitvoering
Effectieve start/einddatum1/05/1530/04/20

Financiering

  • European Commission: 413.552,43 €

ID: 1126025